Bio-Path Holdings Provides Clinical Update and Expansion Plans BPTH_-Provides_Clinical_Update_and_Expansion_Plans
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress BPTH_EHA_Data_Press_Release
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules BPTH_PIPE_PR_20240605
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules BPTH_PR_June_2024_PIPE